Metropolitan Life Insurance CO Aadi Bioscience, Inc. Transaction History

Metropolitan Life Insurance CO

  • $281 Million
  • Q3 2024

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023
BUY
$6.84 - $8.56 $5,554 - $6,950
812 New
812 $5,000
Q4 2022

Jun 14, 2023
BUY
$11.99 - $14.5 $11,198 - $13,543
934 New
934 $12 Million
Q4 2022

Mar 30, 2023
BUY
$11.99 - $14.5 $335 - $406
28 Added 3.09%
934 $11,000
Q4 2022

Feb 15, 2023
BUY
$11.99 - $14.5 $11,198 - $13,543
934 New
934 $11,000
Q2 2022

Jun 20, 2023
BUY
$11.57 - $17.92 $10,482 - $16,235
906 New
906 $11,000
Q2 2022

Mar 30, 2023
SELL
$11.57 - $17.92 $323 - $501
-28 Reduced 3.0%
906 $11,000
Q2 2022

Aug 11, 2022
BUY
$11.57 - $17.92 $10,482 - $16,235
906 New
906 $11,000

Others Institutions Holding AADI

# of Institutions
55
Shares Held
12.6M
Call Options Held
23.8K
Put Options Held
0
View Full List

About Aadi Bioscience, Inc.

AADI Quotes by TradingView
  • Ticker AADI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,016,800
  • Market Cap $63.1M
  • Description
  • Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...
More about AADI
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email